Among people having a history of cryptogenic stroke and left atrial cardiomyopathy, Rivaroxaban exhibited superiority to Aspirin for recurrent stroke prevention, as elucidated from an analytical cross-sectional study.  This study aimed to compare the safety and efficacy of Rivaroxaban and Aspirin.

The neurovascular unit database was searched for 73 individuals with a history of left atrial cardiomyopathy, cryptogenic stroke, and moderate to severe left atrial volume index.

Volunteers were divided into Rivaroxaban and Aspirin groups and then monitored for stroke recurrence as the outcome for two years. For all the volunteers, admission transthoracic echocardiograms were reviewed and the left atrial volume index ≥ 35 mL/m2 was extracted from the reports.

The findings showed that the odds ratio for stroke recurrence in the Aspirin therapy was 11 times higher than the odds ratio in the Rivaroxaban therapy (Odds ratio=11.35), assuming the other variables such as age, gender, hypertension, and diabetes were constant. Thus, people with stroke and cardiomyopathy history are more likely to profit from empirical treatment with Rivaroxaban than Aspirin.